Introduction

The design of clinical trials rests fundamentally on the selection of appropriate endpoints. These endpoints serve as the quantifiable measures that determine whether a therapeutic intervention has achieved its intended effect. Over the past decade, the field has witnessed a paradigm shift from traditional, often rigid endpoints—such as overall survival (OS) in oncology or composite cardiovascular events—toward more nuanced, sensitive, and patient-centric measures. This evolution is driven by the need to accelerate drug development, reduce trial costs, and capture outcomes that truly matter to patients. Recent advances span the integration of digital health technologies, the validation of novel surrogate biomarkers, and the regulatory acceptance of decentralized trial methodologies.

The Shift Toward Digital and Wearable Endpoints

One of the most transformative trends in clinical endpoint research is the incorporation of data from wearable sensors and digital health technologies (DHTs). These tools enable continuous, real-world monitoring of physiological parameters that were previously only assessable during infrequent clinic visits. For instance, in neurological disorders such as Parkinson’s disease, traditional endpoints like the Unified Parkinson’s Disease Rating Scale (UPDRS) are subjective and subject to rater variability. Recent studies have demonstrated that digital measures of gait velocity, tremor frequency, and sleep quality captured via smartwatches correlate strongly with disease progression and can serve as more sensitive endpoints in early-phase trials (Dorsey et al., 2023,Nature Reviews Neurology). Similarly, in pulmonary arterial hypertension, six-minute walk distance has long been the gold standard. However, the FDA has recently accepted digital measures of daily step count and heart rate variability as exploratory endpoints in pivotal trials, recognizing their potential to reflect functional capacity more accurately over time (Corrigan-Curay et al., 2022,Clinical Pharmacology & Therapeutics).

Biomarker-Driven Surrogate Endpoints in Oncology

Oncology remains a hotbed for endpoint innovation, particularly with the rise of targeted therapies and immunotherapies. While overall survival (OS) remains the most definitive endpoint, its use often requires long follow-up periods and large sample sizes. Progression-free survival (PFS) has been a widely accepted surrogate, but its limitations—especially in indolent cancers or when crossover is allowed—have prompted the search for more robust alternatives. A landmark meta-analysis by the FDA’s Oncologic Drugs Advisory Committee validated circulating tumor DNA (ctDNA) clearance as a surrogate endpoint for PFS in early-stage non-small cell lung cancer (NSCLC) (Merker et al., 2024,Journal of Clinical Oncology). The study, encompassing over 4,000 patients, showed that ctDNA clearance at week 8 predicted long-term outcomes with a hazard ratio concordance of 0.8

9. This has led to the incorporation of ctDNA-based endpoints in several ongoing Phase III trials, potentially halving the time needed to reach primary analysis.

Patient-Reported Outcomes and the Emergence of Meaningful Change

Patient-reported outcomes (PROs) have evolved from secondary supportive measures to primary endpoints in many therapeutic areas, particularly in chronic diseases where symptom burden is paramount. The critical advance here is the development of rigorous methodologies for establishing meaningful within-patient change thresholds. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recently published updated guidance on anchor-based methods that link PRO scores to patient global impression of change (PGIC) ratings (Coons et al., 2023,Value in Health). In a pivotal trial for atopic dermatitis, a daily itch severity score (0–10) was validated as a primary endpoint, with a reduction of ≥4 points defined as a clinically meaningful response. This approach not only satisfied regulatory requirements but also demonstrated high correlation with quality-of-life indices, reinforcing the value of patient-centered endpoints in drug approval decisions.

Regulatory Flexibility and the Rise of Composite Endpoints

Regulatory agencies, particularly the FDA and EMA, have shown increasing flexibility in accepting novel endpoints, especially in rare diseases where traditional trial designs are often infeasible. The use of composite endpoints that combine clinical events with biomarker data or functional measures has gained traction. In Duchenne muscular dystrophy, the North Star Ambulatory Assessment (NSAA) was historically used, but its ceiling effects limited sensitivity in older ambulatory patients. A recent Phase III trial successfully employed a novel composite endpoint combining NSAA score, timed rise from floor, and forced vital capacity, achieving statistical significance where individual components had previously failed (McDonald et al., 2024,The Lancet Neurology). This composite was pre-specified and accepted by the EMA under a scientific advice protocol, illustrating a regulatory path forward for complex neurodegenerative conditions.

Future Outlook: Adaptive Endpoints and Artificial Intelligence

The future of clinical trial endpoints lies in adaptive and dynamic measures, enabled by artificial intelligence (AI) and machine learning (ML). Researchers are now exploring the use of multimodal data integration—combining imaging, genomics, wearable data, and PROs—to create composite digital phenotypes that can serve as endpoints in early-phase trials. For example, in Alzheimer’s disease, a recent proof-of-concept study used ML to derive a composite endpoint from magnetic resonance imaging (MRI) volumetric data, cerebrospinal fluid biomarkers, and cognitive test scores, achieving a 40% reduction in required sample size compared to using the traditional Clinical Dementia Rating-Sum of Boxes (CDR-SB) (Ivanidze et al., 2025,Alzheimer’s & Dementia). Such AI-driven endpoints are not yet primary in pivotal trials but are increasingly used in go/no-go decision-making.

Furthermore, the adoption of decentralized clinical trials (DCTs) is reshaping endpoint collection. Remote monitoring via smartphones and home-based spirometry allows for more frequent, ecologically valid data capture. The challenge remains ensuring data quality and inter-device consistency, but ongoing initiatives like the Digital Medicine Society’s (DiMe) V3 framework are establishing standards for verification, analytical validation, and clinical validation of digital endpoints (Goldstein et al., 2023,npj Digital Medicine).

Conclusion

The landscape of clinical trial endpoints is undergoing a profound transformation. From the integration of digital sensors and ctDNA biomarkers to the validation of patient-reported meaningful change, the field is moving toward measures that are more sensitive, more relevant, and more efficient. Regulatory agencies are embracing this shift, provided that rigorous validation accompanies innovation. As AI and decentralized technologies mature, the next generation of endpoints will likely be composite, adaptive, and continuously collected, ultimately accelerating the delivery of effective therapies to patients while ensuring that the outcomes measured are those that truly matter. The challenge for the research community is to maintain scientific rigor without stifling innovation, ensuring that new endpoints are not only novel but also reliable and reproducible across diverse populations.

References